{"id":"r-da-epoch","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL498283","moleculeType":"Small molecule","molecularWeight":"405.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a modified version of the DA-EPOCH chemotherapy backbone, where rituximab (an anti-CD20 monoclonal antibody) is added to enhance immune-mediated tumor cell killing in CD20-positive B-cell lymphomas. The chemotherapy components work through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption, while rituximab provides targeted antibody-dependent cellular cytotoxicity and direct apoptosis induction.","oneSentence":"R-DA-EPOCH is a rituximab-based chemotherapy regimen that combines the anti-CD20 monoclonal antibody rituximab with dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, and doxorubicin (daunorubicin) to treat lymphoid malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:02.253Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"B-cell non-Hodgkin lymphoma"},{"name":"Diffuse large B-cell lymphoma (DLBCL)"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT01516567","phase":"PHASE2","title":"Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2012-04-01","conditions":"Primary Mediastinal Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT05600686","phase":"PHASE2","title":"Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2023-05-24","conditions":"Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","enrollment":24},{"nctId":"NCT01760226","phase":"EARLY_PHASE1","title":"Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-01","conditions":"Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma","enrollment":4},{"nctId":"NCT05270057","phase":"PHASE1","title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-01-26","conditions":"B-cell Lymphoma, Burkitt Lymphoma","enrollment":11},{"nctId":"NCT03054896","phase":"PHASE2","title":"A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-08","conditions":"Richter Syndrome","enrollment":69},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":"AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT00001379","phase":"PHASE2","title":"Treatment and Natural History Study of Lymphomatoid Granulomatosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1995-05-05","conditions":"Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma","enrollment":94},{"nctId":"NCT06871007","phase":"PHASE1, PHASE2","title":"Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma","status":"ENROLLING_BY_INVITATION","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-09-01","conditions":"Primary Mediastinal (Thymic) Large B-cell Lymphoma, Children, Nivolumab","enrollment":22},{"nctId":"NCT04933617","phase":"PHASE1","title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-24","conditions":"Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma","enrollment":8},{"nctId":"NCT03293173","phase":"PHASE2","title":"Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nordic Lymphoma Group","startDate":"2017-08-04","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":120},{"nctId":"NCT03213977","phase":"PHASE3","title":"R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujian Medical University","startDate":"2017-07-10","conditions":"Diffuse Large B-cell Lymphoma","enrollment":475},{"nctId":"NCT03620578","phase":"PHASE2","title":"DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-08-01","conditions":"Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma","enrollment":97},{"nctId":"NCT06188676","phase":"PHASE3","title":"Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2022-04-01","conditions":"Primary Mediastinal Lymphoma","enrollment":100},{"nctId":"NCT01193842","phase":"PHASE1, PHASE2","title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-06","conditions":"AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, Ann Arbor Stage I Diffuse Large B-Cell Lymphoma","enrollment":107},{"nctId":"NCT05109741","phase":"NA","title":"Internet-based Psychodynamic Therapy Compared to Behavioral Activation - a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2021-10-04","conditions":"Depression","enrollment":189},{"nctId":"NCT01030900","phase":"PHASE2","title":"Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-22","conditions":"Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":50},{"nctId":"NCT03036904","phase":"PHASE1","title":"Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-02-06","conditions":"Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma","enrollment":31},{"nctId":"NCT02481310","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2015-10-28","conditions":"Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":38},{"nctId":"NCT05164770","phase":"PHASE3","title":"Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-03-01","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B Cell Lymphoma","enrollment":160},{"nctId":"NCT05097443","phase":"PHASE3","title":"Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2021-04-15","conditions":"High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma","enrollment":130},{"nctId":"NCT00118209","phase":"PHASE3","title":"Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2005-05","conditions":"Large B Cell Lymphoma","enrollment":524},{"nctId":"NCT01445535","phase":"PHASE1","title":"Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-01-13","conditions":"T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma","enrollment":15},{"nctId":"NCT04992377","phase":"PHASE2","title":"R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2021-08-30","conditions":"Richter Transformation","enrollment":30},{"nctId":"NCT03023878","phase":"PHASE2","title":"Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-13","conditions":"High-risk Diffuse Large B-Cell Lymphoma","enrollment":47},{"nctId":"NCT04432714","phase":"PHASE1, PHASE2","title":"Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2020-06-09","conditions":"DLBCL, Untreated, MYC Gene Rearrangement","enrollment":81},{"nctId":"NCT04152577","phase":"PHASE4","title":"R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2019-06-05","conditions":"Lymphoma, B-Cell","enrollment":200},{"nctId":"NCT02142049","phase":"PHASE1, PHASE2","title":"Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-05","conditions":"Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory","enrollment":35},{"nctId":"NCT03479918","phase":"PHASE3","title":"R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)","status":"UNKNOWN","sponsor":"Elena N.Parovichnikova","startDate":"2018-03-15","conditions":"Lymphoma, High-Grade","enrollment":80},{"nctId":"NCT02815397","phase":"PHASE2","title":"DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma","status":"TERMINATED","sponsor":"Rush University Medical Center","startDate":"2016-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":2},{"nctId":"NCT03018626","phase":"PHASE3","title":"R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-07-27","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":402},{"nctId":"NCT03188198","phase":"PHASE2","title":"Risk Adapted Therapy in Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2016-06-01","conditions":"Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT02777736","phase":"PHASE3","title":"CNS Prophylaxis in Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Czech Lymphoma Study Group","startDate":"2015-07","conditions":"Diffuse Large B-cell Lymphoma","enrollment":500},{"nctId":"NCT01914718","phase":"PHASE2","title":"Dose-adjusted EPOCH-R in MYC Positive DLBCL","status":"TERMINATED","sponsor":"Fudan University","startDate":"2013-02","conditions":"Diffuse Large B-cell Lymphoma","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":43,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-DA-EPOCH","genericName":"R-DA-EPOCH","companyName":"Fujian Medical University","companyId":"fujian-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-DA-EPOCH is a rituximab-based chemotherapy regimen that combines the anti-CD20 monoclonal antibody rituximab with dose-adjusted etoposide, prednisone, oncovin (vincristine), cyclophosphamide, and doxorubicin (daunorubicin) to treat lymphoid malignancies. Used for B-cell non-Hodgkin lymphoma, Diffuse large B-cell lymphoma (DLBCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}